Henry Ford Health System to Present Webinar on Positive Clinical Impact of T2 Biosystems’ T2Candida® Panel
May 19 2017 - 7:30AM
T2 Biosystems, Inc., (NASDAQ:TTOO), a company developing innovative
diagnostic products to improve patient health and deliver a strong
economic return to healthcare institutions, announced today the
company, in collaboration with LabRoots, will host a webinar
on May 22, 2017, beginning at 10:00 a.m. PT/1:00 p.m. ET.
The webinar will be hosted by renowned clinical expert Dr.
George Alangaden, Senior Staff Physician Director, Transplant
Infectious Diseases, Medical Director of Infection Prevention,
Henry Ford Hospital System (HFHS). Dr. Alangaden will discuss how
HFHS implemented T2MR® and the T2Candida Panel as part of their
sepsis protocol for the management of candidemia. He will also
share the positive impact T2MR and T2Candida has had at HFHS on
patient length of stay and antifungal use.
To read more on this free webinar, learn about the continuing
education credits offered, or to register, click here.
About George Alangaden MD, FACP, FIDSA
Dr. Alangaden received his medical degree from the University of
Bombay and has since completed post-graduate training in India, the
United Kingdom and the United States. Dr. Alangaden is the Director
of Transplant Infectious Diseases and Director of Infection Control
and Prevention at Henry Ford Hospital and Transplant Institute.
Dr. Alangaden's research interest lies in the epidemiology and
outcomes of infections in immunocompromised patients and transplant
recipients. He is also involved and well-published in the areas of
research related to tuberculosis and nosocomial infections,
especially Clostridium difficile.
About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic
products to improve patient health. With the FDA-cleared T2Dx®
Instrument and T2Candida Panel targeting sepsis and a range of
additional products in development, T2 Biosystems is an emerging
leader in the field of in vitro diagnostics. The Company is
utilizing its proprietary T2 Magnetic Resonance technology, or
T2MR, to develop a broad set of applications aimed at lowering
mortality rates, improving patient outcomes and reducing the cost
of healthcare by helping medical professionals make targeted
treatment decisions earlier. T2MR enables the fast and sensitive
detection of pathogens, biomarkers and other abnormalities in a
variety of patient sample types, including whole blood. For more
information, please visit www.t2biosystems.com.
About LabRoots
LabRoots is the leading scientific social networking
website and producer of educational virtual events and webinars.
Contributing to the advancement of science through content sharing
capabilities, LabRoots is a powerful advocate in amplifying global
networks and communities. Founded in 2008, LabRoots emphasizes
digital innovation in scientific collaboration and learning and is
a primary source for current scientific news, webinars, virtual
conferences and more. LabRoots has grown into the world’s largest
series of virtual events within the Life Sciences and Clinical
Diagnostics community.
Company Contact:
Darlene Deptula-Hicks, T2 Biosystems
SVP & Chief Financial Officer
ddeptula@t2biosystems.com
603-553-5803
Media Contact:
Matthew McKillip, T2 Biosystems
mmckillip@t2biosystems.com
518-577-3466
Investor Contact:
Tucker Elcock, Teneo Strategy
Tucker.Elcock@teneostrategy.com
212-886-9319
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Aug 2024 to Sep 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Sep 2023 to Sep 2024